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AbstrACt
Objectives To evaluate potential gaps in preventive 
medical therapy and healthy lifestyle practices among 
symptomatic patients with suspected coronary artery 
disease (CAD) seeing primary care physicians and 
cardiologists and how gaps vary by sociodemographic 
characteristics and baseline cardiovascular risk.
Design Cross-sectional study assessing potential 
preventive gaps.
Participants 10 003 symptomatic outpatients evaluated 
by primary care physicians, cardiologists or other 
specialists for suspected CAD.
setting PROspective Multicenter Imaging Study for 
Evaluation of Chest Painfrom 2010 to 2014.
Measures Primary measures were absence of an 
antihypertensive, statin or angiotensin-converting enzyme 
inhibitor/angiotensin receptor blocker for renal protection 
in patients with hypertension, dyslipidaemia or diabetes, 
respectively, and being sedentary, smoking or being obese.
results Preventive treatment gaps affected 14% 
of patients with hypertension, 36% of patients with 
dyslipidaemia and 32% of patients with diabetes. Overall, 
49% of patients were sedentary, 18% currently smoked 
and 48% were obese. Women were significantly more 
likely to not take a statin for dyslipidaemia and to be 
sedentary. Patients with lower socioeconomic status were 
also significantly more likely to not take a statin. Compared 
with Whites, Blacks were significantly more likely to 
be obese, while Asians were less likely to smoke or be 
obese. High-risk patients sometimes experienced larger 
preventive care gaps than low-risk patients. For patients 
with dyslipidaemia, the presence of a treatment gap was 
associated with a higher risk of an adverse event (HR 1.35, 
95% CI 1.02 to 1.82).
Conclusions Among contemporary, symptomatic 
patients with suspected CAD, significant gaps exist in 
preventive care and lifestyle practices, and high-risk 
patients sometimes had larger gaps. Differences by sex, 
age, race/ethnicity, socioeconomic status and geography 
are modest but contribute to disparities and have 
implications for improving opulation health. For patients 
with dyslipidaemia, the presence of a treatment gap was 
associated with a higher risk of an adverse event.
Clinical trial registration Clinical  Trials. gov identifier 
NCT01174550.
Preventive medical care and lifestyle prac-
tices reduce the risk of adverse cardiovascular 
events1 2 and may influence how likely a patient 
is to present to their primary care physician 
or cardiologist with symptoms suggestive of 
coronary artery disease (CAD). In the USA, 
approximately 4 million of these patients are 
referred for outpatient cardiac stress testing or 
coronary CT angiography (CTA) each year.3 
Although most have significant risk factors 
strengths and limitations of this study
 ► The study had a large sample size with an N of 
10003 patients.
 ► Measures of preventive lifestyle practices were 
gathered through self-report; errors or inaccuracies 
in self-report could therefore affect our results.
 ► There may have been patients whose hypertension 
or dyslipidaemia were well  controlled with dietary 
changes and exercise alone.
 ► Among patients with diabetes, we did not have 
clinical information about albuminuria, so there 
may have been patients for whom the benefit 
of angiotensin-converting enzyme inhibitor or 
angiotensin receptor blocker therapy was uncertain.
 ► Use of body mass index (BMI) as a surrogate for 
body fatness and obesity identification is also 
vulnerable to misclassification, since sex, age, race/
ethnicity and muscle mass influence the relationship 
between BMI and excess fat.
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for adverse cardiovascular events, such as hypertension, 
dyslipidaemia and diabetes,4 5 little is known about their 
preventive medical and lifestyle practices prior to presen-
tation, the extent to which these preventive measures 
differ from national recommendations and guidelines6–9 
or their relationship with sociodemographic and socio-
economic disparities. Understanding these patterns 
and characterising the magnitude of medical or lifestyle 
gaps—that is, the difference between recommended 
preventive care and actual preventive care—is a critical 
step toward preventing disease and reducing adverse 
cardiovascular events in this population, independent 
of the outcome of diagnostic testing. Further, if preven-
tive care varies by sociodemographic characteristics, this 
variation may contribute to important health disparities 
and identify populations in need of specific targeting. To 
identify opportunities for improving preventive care in 
this population, we used data from symptomatic patients 
in the PROspective Multicenter Imaging Study for Evalu-
ation of Chest Pain (PROMISE) to (1) evaluate potential 
gaps in preventive medical therapy among patients with 
hypertension, dyslipidaemia or diabetes; (2) determine 
the extent to which these gaps differed by patients’ base-
line risk; (3) evaluate gaps in healthy lifestyle practices, as 
defined by being sedentary, smoking or being obese and 
(4) determine which gaps vary by sex, age, race/ethnicity, 
socioeconomic status and geography.
MethODs
study design
Methods used in PROMISE have been described previ-
ously.4 10 The study protocol was approved by the local 
or central institutional review board at each coordinating 
centre and at each enrolling site in North America. We 
enrolled symptomatic outpatients without diagnosed 
CAD whose physicians believed that non-urgent, non-in-
vasive cardiovascular testing was necessary for the evalua-
tion of suspected CAD. After providing written informed 
consent, 10 003 eligible patients were randomly assigned 
to either anatomical testing with CTA or functional testing 
with exercise electrocardiography, nuclear stress or 
stress echocardiography.10 Enrollment began on 27 July 
2010 and was completed on 19 September 2013. All the 
patients were followed until 31 October 2014. Analyses 
were performed in 2016.
Gaps in preventive medications and lifestyle practices
At the time of enrollment, information about preventive 
medication use and lifestyle practices was collected by 
the clinical sites through patient report, chart review and 
other clinical sources. We focused on six potential gaps in 
preventive care that have been demonstrated to increase 
the risk of cardiovascular disease1 11: absence of an anti-
hypertensive medication in patients with hypertension, 
absence of a statin in patients with dyslipidaemia, absence 
of an angiotensin-converting enzyme inhibitor or angio-
tensin receptor blocker (ACEi/ARB) for renal protection 
in patients with diabetes, being sedentary, smoking and 
being obese, as determined by a body mass index (BMI) 
exceeding 30. Because patients had to be eligible for 
randomisation to either CTA or functional testing, no 
patients known to have renal dysfunction were enrolled.
hypertension, dyslipidaemia and diabetes
Because PROMISE was a pragmatic trial, diagnoses were 
identified and defined by physicians at the participating 
clinics rather than with study-specific criteria. Among 
our symptomatic patients, absence of antihypertensive 
medication in patients with hypertension was defined as 
a preventive care gap because of evidence that treating 
patients with this comorbidity reduces the risk of cardio-
vascular events12 and because treatment is consistent 
with recommendations issued by the American Society 
of Hypertension, International Society of Hyperten-
sion13 and American Heart Association.14 Absence of 
a statin in patients with dyslipidaemia was considered a 
preventive care gap because statin use in primary and 
secondary prevention has been shown to reduce cardio-
vascular risk.15 16 The median atherosclerotic cardiovas-
cular disease (ASCVD) score in our population was 11.3% 
with an IQR of 6.1% to 19.8%, well above the 10-year risk 
threshold of 7.5% for treatment in most participants.17 
Applying lower ASCVD thresholds for statin therapy has 
also been shown to be cost-effective.18 Absence of an 
ACEi/ARB for renal protection in patients with diabetes 
was considered a preventive care gap because the vast 
majority of diabetics in our population were hypertensive 
(79.9%) and prophylactic use of ACEi/ARBs reduces the 
incidence of albuminuria,19–21 which has been shown to 
be a risk factor for cardiovascular22 and overall mortality 
in patients with diabetes.23 24
Physical inactivity, smoking and obesity
Being sedentary, smoking and being obese have all been 
demonstrated to increase cardiovascular risk and there-
fore represent important gaps in preventive lifestyle 
practices.1 We assessed the prevalence of these lifestyle 
practices across all patients in our cohort. To assess activity 
level, we asked, “During the past month, did you partic-
ipate in any physical activities or exercise regularly (one 
or more times per week)? Examples include: running, 
aerobics, golf, gardening, walking, etc” (yes or no). To 
assess smoking, we asked, “Have you smoked in the past 
2 weeks?” (yes or no).
Demographics and socioeconomics
We focused on disparities in prevention by sex, age, race/
ethnicity, socioeconomic status and geography. Race/
ethnicity was reported by the patient and categorised into 
the following mutually exclusive groups: White; Black; 
American Indian/Alaska Native, Native Hawaiian/Other 
Pacific Islanders; Asian (not including any Hispanics) 
and Hispanics (from any racial/ethnic group).25 Socio-
economic status was defined by the median household 
income of the patient’s zip code based on data extracted 
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from 2010 US Census Bureau American Community 
Survey Data (5-year estimates), similar to prior work.26–29 
Socioeconomic status was categorised into quartiles 
from lowest to highest median household income (low, 
medium low, medium high and high). We used the 
following US Census categories for geographic regions: 
Northeast, Midwest, West and South.
statistical analysis
Analyses were based on patient status at presentation for 
CAD evaluation. p Values of less than 0.05 were consid-
ered significant. We estimated summary statistics for gaps 
in preventive care and lifestyle practices and constructed 
multivariable logistic regression models to assess the 
association of patients’ sociodemographic characteristics 
(sex, age, race/ethnicity, socioeconomic status and geog-
raphy) at presentation with these gaps, while controlling 
for baseline risk (for blood pressure: systolic <140 mm 
Hg and diastolic <90 mm Hg, systolic 140 to 159 mm Hg 
or diastolic 90 to 99 mm Hg, and systolic ≥160 mm Hg or 
diastolic ≥100 mm Hg; for ASCVD: <7.5%, 7.5% to <15% 
and ≥15%), other clinical characteristics and physician 
specialty (see online supplementary appendix tables 
1.1–1.3 for detailed clinical characteristics and online 
supplementary appendix tables 2.1 and 2.2 for fully 
reported regression results). In addition to estimating 
covariate-adjusted ORs and their corresponding 95% CIs, 
the fitted models were used to compute covariate-ad-
justed probabilities30 (also known as ‘predictive margins’) 
of gaps in preventive medication use and healthy life-
style practices, with stratification by sociodemographic 
characteristics. In these analyses, the regression models 
predict proportions for each sociodemographic charac-
teristic, while holding the distribution of all other covari-
ates constant. We excluded 4% of patients in PROMISE 
from our multivariable analyses because we were unable 
to match their reported zip codes to US Census Bureau 
data. Statistical analyses were performed using SAS V.9.2 
or higher (SAS Institute).
results
symptomatic patients: characteristics and baseline risk
Characteristics of the 10 003 symptomatic patients (88% 
with chest pain/dyspnoea, 12% with other symptoms) 
presenting to their primary care physicians, cardiologists 
or other specialists are summarised in table 1. The median 
age of the cohort was 60.0 years (IQR, 54.4–66.0 years), 
and 52.7% were women. Whites composed 77.4% of the 
cohort, and Blacks and Hispanics composed 10.8% and 
7.7%, respectively. Asians composed 2.5% of the cohort, 
and people of other/unknown race/ethnicity composed 
1.6% of the cohort. Patients in the lowest socioeconomic 
quartile lived in zip codes with a median household 
income less than US$42 610, while patients in the highest 
socioeconomic quartile lived in zip codes with median 
household income of at least US$71 059 annually.
Table 1 Demographics and presenting characteristics for 
all patients
Characteristic
All patients
(n=10 003)
Female (%) 5270/10 003 (52.7%)
Median age (IQR), years 60.0 (54.4–66.0)
Age (%), years
  45–64 7111/10 003 (71.1%)
  65–79 2711/10 003 (27.1%)
  80+ 181/10 003 (1.8%)
Race/ethnicity (%)
  Hispanic or Latino 767/9945 (7.7%)
  Not Hispanic or Latino-White 7693/9945 (77.4%)
  Not Hispanic or Latino-Black 1071/9945 (10.8%)
  Not Hispanic or Latino-Asian 250/9945 (2.5%)
  Not Hispanic or Latino-Other 164/9945 (1.6%)
Socioeconomic status (minimum, 
maximum income), $*
  Low 11 118, 42 610
  Medium-low 42 613, 54 149
  Medium-high 54 167, 71 034
  High 71 059, 184 338
US region†
  Midwest 2208/9690 (22.8%)
  Northeast 1439/9690 (14.9%)
  South 3999/9690 (41.3%)
  West 2044/9690 (21.1%)
Cardiac risk factors
  BMI ≥30 (%) (median 29.7, IQR 
26.3–33.9)
4724/9907 (47.7%)
  Hypertension (%) 6501/10 002 (65.0%)
  Diabetes (%) 2144/10 002 (21.4%)
  Dyslipidaemia (%) 6767/10 002 (67.7%)
  Family history of premature CAD 
(%)
3202/9970 (32.1%)
  Peripheral arterial disease or 
cerebrovascular disease (%)
552/10 003 (5.5%)
  CAD risk equivalent (%) 2531/10 003 (25.3%)
  Metabolic syndrome (%) 3772/10 003 (37.7%)
  Current tobacco use (%) 1773/10 000 (17.7%)
  Regular exercise (%) 5116/9982 (51.3%)
  History of depression (%) 2058/10 000 (20.6%)
Risk scores
  Mean Diamond and Forrester 
score (SD) [n]
53 (20.14) [10 003]
  Mean ASCVD Pooled Cohort Risk 
Prediction (2013) (SD) [n]
15 (11.75) [9901]
Medication use (%)
  Aspirin 4280/9569 (44.7%)
Continued
4 Ladapo JA, et al. BMJ Open 2017;7:e016364. doi:10.1136/bmjopen-2017-016364
Open Access 
Preventive medical and lifestyle gaps
Overall, the prevalences of hypertension, dyslipidaemia 
and diabetes were 65.0% (n=6501), 67.7% (n=6767) 
and 21.4% (n=2144), respectively. Among these symp-
tomatic patients, preventive treatment gaps affected 
14% of patients with hypertension, 36% of patients with 
dyslipidaemia and 32% of patients with diabetes. In our 
examination of preventive lifestyle practices, 49% of all 
patients were sedentary, 18% were current smokers and 
48% were obese.
Association of preventive care gaps with sex, age and race/
ethnicity
Adjusted ORs for the association between patient char-
acteristics and preventive care gaps are presented in 
table 2 and covariate-adjusted probabilities of preventive 
care gaps are presented in figures 1 and 2. Women were 
significantly more likely than men to not take a statin 
for dyslipidaemia (OR 1.33, 95% CI 1.18 to 1.50) and 
to be sedentary (OR 1.55, 95% CI 1.41 to 1.70). Older 
patients were significantly less likely than the youngest 
patients to not be taking a statin for dyslipidaemia (65–79 
years: OR 0.64, 95% CI 0.55 to 0.75; ≥80 years: OR 0.59, 
95% CI 0.38 to 0.92) and to smoke (65–79 years: OR 0.23, 
95% CI 0.19 to 0.27; ≥80 years: OR 0.04, 95% CI 0.01 to 
0.13). There were no significant differences in preventive 
medications by patients’ race/ethnicity, but differences 
existed in preventive lifestyle practices: compared with 
White patients, Blacks were significantly more likely to be 
obese (OR 1.55, 95% CI 1.31 to 1.84), while Asians were 
less likely to smoke (OR 0.49, 95% CI 0.30 to 0.80) or 
be obese (OR 0.16, 95% CI 0.11 to 0.24). There were no 
significant differences in preventive lifestyle practices of 
Hispanics compared with Whites.
Variation in preventive care gaps between higher and lower 
risk symptomatic patients
The prevalence of preventive medical therapy gaps varied 
by patient risk. Among symptomatic patients with hyper-
tension, those at the highest overall cardiovascular risk 
(ASCVD ≥15%) were less likely to not be on an antihyper-
tensive than patients at the lowest overall cardiovascular 
risk (ASCVD <7.5%) (OR 0.45, 95% CI 0.34 to 0.58), but 
patients with the highest blood pressure (≥160/100) 
were more likely to not be on an antihypertensive than 
patients with the lowest blood pressure (<140/90) (OR 
1.54, 95% CI 1.19 to 1.99). Among patients with dyslip-
idaemia, those at the highest overall cardiovascular risk 
(OR 1.22, 95% CI 1.01 to 1.47) and with the highest 
blood pressure (OR 1.28, 95% CI 1.03 to 1.59) were more 
likely to not be on a statin, compared with patients with 
the lowest cardiovascular risk or lowest blood pressure. 
Among patients with diabetes, those at the highest overall 
cardiovascular risk were less likely to not be on an ACEi/
ARB than patients at the lowest overall cardiovascular risk 
(OR 0.64, 95% CI 0.42 to 0.97) (see online supplemen-
tary appendix table 2.1).
For the combined endpoint of death, myocardial infarc-
tion or hospitalisation for unstable angina, there was no 
association between having a treatment gap and the risk 
of an adverse event among patients with hypertension or 
diabetes. However, for patients with dyslipidaemia, the 
presence of a treatment gap was associated with a higher 
risk of an adverse event (HR 1.35, 95% CI 1.02 to 1.82).
Association of preventive care gaps with socioeconomic 
status/geography
Compared with symptomatic patients with the highest 
socioeconomic status, patients with a medium-high socio-
economic status were more likely to not receive an anti-
hypertensive for hypertension (OR 1.25, 95% CI 1.01 
to 1.55), while patients with the lowest socioeconomic 
status were more likely to not receive a statin for dyslipi-
daemia (OR 1.20, 95% CI 1.02 to 1.41) (table 2, figure 2). 
Patients with lower socioeconomic status were also more 
likely to be sedentary (low: OR 1.45, 95% CI 1.28 to 1.65; 
medium low: OR 1.20, 95% CI 1.07 to 1.36; medium high: 
OR 1.18, 95% CI 1.05 to 1.32) and smoke (low: OR 2.00, 
95% CI 1.68 to 2.38; medium low: OR 1.63, 95% CI 1.38 
to 1.94; medium high: OR 1.52, 95% CI 1.28 to 1.80) than 
patients with the highest socioeconomic status (table 2), 
and these differences were more pronounced as socio-
economic status fell. Regional differences were common: 
compared with patients in the South, patients living in 
the West were more likely to not receive antihypertensives 
for hypertension (OR 1.32, 95% CI 1.08 to 1.63) and not 
Characteristic
All patients
(n=10 003)
  Statin 4389/9569 (45.9%)
  Beta-blocker 2399/9569 (25.1%)
  ACE inhibitor or ARB 4194/9569 (43.8%)
Primary presenting symptoms (%)
  Chest pain 7272/9996 (72.7%)
  Dyspnoea 1490/9996 (14.9%)
  Other 1234/9996 (12.3%)
Type of angina (%)
  Typical 1166/10 003 (11.7%)
  Atypical 7773/10 003 (77.7%)
  Non-cardiac 1064/10 003 (10.6%)
Physician specialty (%)
  Cardiology 8662/10 003 (86.6%)
  Internal medicine 565/10 003 (5.6%)
  Other 776/10 003 (7.8%)
*Median household income (in US$) is used as a surrogate for 
socioeconomic status.
†143 patients had missing zip code data, and 170 patients had 
zip codes that were not reported in 2010 Census American 
Community Survey data.
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor 
blocker; ASCVD, atherosclerotic cardiovascular disease; BMI, 
body mass index; CAD, coronary artery disease.
Table 1 Continued 
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receive statins for dyslipidaemia (OR 1.31, 95% CI 1.13 
to 1.52). Compared with patients in the South, patients 
in all other US regions were less likely to be sedentary 
(Midwest: OR 0.58, 95% CI 0.52 to 0.65; Northeast: OR 
0.63, 95% CI 0.55 to 0.72; West: OR 0.68, 95% CI 0.61 to 
0.77), and patients in the West were less likely to smoke 
(OR 0.76, 95% CI 0.65 to 0.90), while patients in the 
Midwest were more likely to be obese (OR 1.23, 95% CI 
1.08 to 1.41).
DisCussiOn
In the PROMISE trial population, we found that symp-
tomatic patients presenting to their primary care physi-
cians, cardiologists or other specialists with suspected 
CAD have a high prevalence of risk factors for adverse 
cardiovascular events, with many of these risk factors 
representing missed opportunities to improve preventive 
medical care and lifestyle practices. We identified popula-
tions that should be targeted for interventions based on 
their sex, age, race/ethnicity, socioeconomic status and 
geography. While some of the preventive care gaps were 
smaller in symptomatic patients at higher risk, others 
were larger or unassociated with baseline risk. Finally, 
our results support the notion that wider adherence to 
preventive medication and lifestyle practices may alter 
the epidemiology of chest pain presentations and reduce 
the incidence of evaluations for CAD.31
Our findings of gaps in preventive care and differences 
in these gaps across important sociodemographic charac-
teristics complement the work of others. For example, in 
a study of patients with cardiovascular disease in the US 
Veterans Affairs health system, women were less likely to 
receive a statin than men.32 In another study of patients 
with peripheral artery disease, patients living in low socio-
economic status areas, as defined by median household 
income, were less likely to receive statins than patients 
living in higher socioeconomic status areas.28 Racial/
ethnic differences in exercise participation, smoking 
and obesity have also been reported.25 33 However, our 
work extends and broadens the findings of these studies 
because (1) our study focused on actively symptomatic 
patients, whose presentation may be attributable to gaps 
in prevention and (2) we simultaneously accounted for a 
wider range of sociodemographic characteristics.
By assessing the relationship between baseline risk and 
preventive gaps, we showed that there was a trend towards 
lower preventive care gaps among symptomatic patients 
with high ASCVD scores, but higher preventive care gaps 
among symptomatic patients with elevated blood pres-
sure. Our data also reflect more recent care preventive 
patterns across a broad geographic and socioeconomic 
Figure 1 Preventive medical therapy and lifestyle practices at presentation, by sex, age and race/ethnicity. The bars represent 
covariate-adjusted probabilities of a preventive care gap, based on the multivariate models reported in table 2. The reference 
groups for tests of statistical significance are male sex, 45–64 years old and White race/ethnicity. ACEi/ARB, angiotensin-
converting enzyme inhibitor or angiotensin receptor blocker. We assessed antihypertensive use in hypertensives, statin use in 
dyslipidemics, and ACEi/ARB in diabetics. *P<0.05
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sample. Our explicit inclusion of multiple racial/ethnic 
groups—particularly Asians—is also an advance for 
research in cardiovascular disease disparities, where 
previous comparisons have often been limited to Whites 
and Blacks only.29 33–35 Our findings of disparities in 
preventive care are therefore more comprehensive and 
robust.
Similar to other studies of gaps in preventive care, our 
results highlight the importance of public health and 
policy initiatives aimed at bolstering primary prevention. 
Policy initiatives, such as the Million Hearts campaign, 
now leverage public–private partnerships and large invest-
ments in state and community programme to improve 
aspirin use in patients with CAD, blood pressure control 
among patients with hypertension, cholesterol manage-
ment and smoking cessation.36 37 In addition, our find-
ings reinforce the potential benefits of public and private 
policies that eliminate marginal cost-sharing for choles-
terol and hypertension screening, obesity screening and 
counselling and smoking cessation services.38 Gaps in 
preventive care also highlight opportunities for making 
diagnostic testing a ‘teachable moment’ for symptomatic 
patients in this population—and for the primary care 
physicians and cardiologists caring for them. We did not 
examine the association of gaps in care with subsequent 
imaging, CAD diagnosis or invasive coronary angiography. 
Figure 2 Preventive medical therapy and lifestyle practices at presentation. The bars represent covariate-adjusted 
probabilities of a preventive care gap, based on the multivariate models reported in table 2. The reference groups for tests of 
statistical significance are high socioeconomic status and South region. ACEi/ARB, angiotensin-converting enzyme inhibitor or 
angiotensin receptor blocker. We assessed antihypertensive use in hypertensives, statin use in dyslipidemics, and ACEi/ARB in 
diabetics.*P<0.05
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In prior work, we showed that new initiation of an aspirin, 
statin, beta-blocker or ACEi/ARB was not associated with 
the rate of adverse cardiovascular events over a median 
follow-up period of 25 months in adjusted models.39 We 
have also reported that absence of hypertension, dyslipi-
daemia and tobacco use are associated with a lower rate 
of adverse cardiovascular events.40 We also found that 
treatment gaps among patients with hypertension or 
diabetes were not associated with an increased risk of 
adverse cardiovascular events. In contrast, treatment gaps 
among patients with dyslipidaemia were associated with 
an increased risk of adverse cardiovascular events.
Our study has important limitations. There may have 
been patients whose hypertension or dyslipidaemia were 
well controlled with dietary changes and exercise alone. 
Among patients with diabetes, we did not have clinical 
information about albuminuria, so there may have been 
patients for whom the benefit of ACEi/ARB therapy was 
uncertain. In addition, our measures of preventive life-
style practices were gathered through self-report; errors 
or inaccuracies in self-report could therefore affect our 
results. Our use of BMI as a surrogate for body fatness 
and obesity identification is also vulnerable to misclassi-
fication, since sex, age, race/ethnicity and muscle mass 
influence the relationship between BMI and excess fat. In 
terms of methodological strengths, our analyses included 
adjustments for multiple clinical characteristics and 
collected detailed race/ethnicity information. In addi-
tion, our study population was diverse in age, sex, income 
and geography. In terms of methodological weaknesses, 
because the study population was primarily composed of 
white patients, the study results may not be generalisable 
to all populations.
In conclusion, among contemporary, symptomatic 
patients presenting to primary care physicians, cardiol-
ogists and other specialists with suspected CAD, oppor-
tunities exist to bridge significant gaps in preventive 
care and lifestyle practices and reduce the incidence of 
future CAD. Differences by sex, age, race/ethnicity, socio-
economic status and geography tend to be modest but 
contribute to disparities and identify populations that 
should be targeted for interventions.
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